NEBIVOLOL V LEChENII ARTERIAL'NOY GIPERTENZII U BOL'NYKh VYSOKOGO RISKA


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

This review describes the main issues related to the use of nebivolol in patients with arterial hypertension (AH). The features of nebivolol are discussed in detail, as it is highly selective 3rd generation β-blocker having the action on the endothelial function and stimulating the synthesis of nitric oxide. Possible mechanism of organoprotective action of the drug ids described. Evidence of antihypertensive efficacy is presented. The effects of nebivolol on the state of the target organs in arterial hypertension, the metabolic effects of nebivolol, and the potentias for the ose of the drug in patients with diabetes mellitus, obesity, and metabolic syndrome are considered.

全文:

受限制的访问

作者简介

L. Minushkina

Email: minushkina@mail.ru

参考

  1. Izzo R., de Simone G., Trimarco V., Gerdts E., Giudice R., Vaccaro O., De Luca N., Trimarco B. Hypertensive target organ damage predicts incident diabetes mellitus. Eur. Heart. J. 201;34(44):3419-26.
  2. Mancia G., Fagard R., Narkiewicz K., Redon J., ZanchettiA., Böhm M., Christiaens T., Cifkova R., De Backer G., Dominiczak A., Galderisi M., Grobbee D.E.,Jaarsma T., Kirchhof P., Kjeldsen S.E., Laurent S., Manolis A.J., Nilsson P.M., Ruilope L.M., Schmieder R.E., Sirnes P.A., Sleight P., Viigimaa M., Waeber B., Zannad F.; Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology.Task Force for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology. 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press. 2014;23(1):3-16.
  3. Korkmaz O., Sarac B., Göksel S., Yildirim S., Berkan O., Bagcivan I. Labetalol, nebivolol, and propranolol relax human radial artery used as coronary bypass graft. Thorac. Cardiovasc. Surg. 2015;149(4):1036-40.
  4. Perros F., Ranchoux B., Izikki M., Bentebbal S., Happ C, Antigny F., Jourdon P., Dorfmüller P., Lecerf F., Fadel E., Simonneau G., Humbert M., Bogaard H.J., Eddahibi S. Nebivolol for improving endothelial dysfunction, pulmonary vascular remodeling, and right heart function in pulmonary hypertension. J. Am. Coll. Cardiol. 2015;65(7):668-80.
  5. Okamoto L.E., Gamboa A., Shibao C.A., Arnold A.C., Choi L., Black B.K., Raj S.R., Robertson D., Biaggioni I. Nebivolol, but not metoprolol, lowers blood pressure in nitric oxide-sensitive human hypertension. Hypertension. 2014;64(6):1241-47.
  6. Lewin A., Punzi H., Luo X., Stapff M. Nebivolol monotherapy for patients with systolic stage II hypertension: results of a randomized, placebocontrolled trial. Clin. Ther. 2013;35(2):142-52.
  7. Lewin A., Lasseter K.C., Dong F., Whalen J.C. Nebivolol withdrawal results in blood pressure returning toward pretreatment levels, but without rebound symptoms: phase IV randomized trial. J. Am. Soc. Hypertens. 2012;6(3):228-36.
  8. AcelajadoM.C.,PisoniR.,DudenbostelT.,OparilS., Calhoun D.A, Glasser S.P. Both morning and evening dosing of nebivolol reduces trough mean blood pressure surge in hypertensive patients. J. Am. Soc. Hypertens. 2012;6(1):66-72.
  9. Yazici H.U., Ozduman H., Aydar Y., Birdane A. Effects of metoprolol and nebivolol on exercise blood pressure in patients with mild hypertension. ScientificWorldJournal. 2013 29;2013:608-83.
  10. Redon J., Pascual-Izuel J.M., Rodilla E., Vicente A., Olivan J., Bonet J., Torguet J.P., Calaforra O., Almirall J. Effects of nebivolol and atenolol on central aortic pressure in hypertensive patients: a multicenter, randomized, double-blind study. Blood Press. 2014;23(3):181-88.
  11. Badar V.A., Hiware S.K., Shrivastava M.P., Thawani V.R., Hardas M.M. Comparison of nebivolol and atenolol on blood pressure, blood sugar, and lipid profile in patients of essential hypertension. Indian J. Pharmacol. 2011;43(4):437-40.
  12. Sayin M.R., Aydin M., Dogan S.M., Karabag T., Cetiner M.A., Aktop Z. Aortic elastic properties: effects of carvedilol versus nebivolol. Herz. 2013;38(3):299-305.
  13. Czuriga I., Riecansky I., Bodnar J., Fulop T., Kruzsicz V., Kristof E., Edes I.; NEBIS Investigators; NEBIS Investigators Group. Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS). Cardiovasc Drugs Ther. 2003;17(3):257-63.
  14. Weiss R.J., Stapff M., Lin Y. Placebo effect and efficacy of nebivolol in patients with hypertension not controlled with lisinopril or losartan: a phase IV, randomized, placebo-controlled trial. Am. J. Cardiovasc. Drugs. 2013;13(2):129-40.
  15. Neutel J.M., Giles T.D., Punzi H., Weiss R.J., Li H., Finck A. Long-term safety of nebivolol and valsartan combination therapy in patients with hypertension: an open-label, single-arm, multicenter study. J. Am. Soc. Hypertens. 2014;8(12):915-20.
  16. Weiss R.J., Saunders E., Greathouse M. Efficacy and tolerability of nebivolol in stage I-II hypertension: a pooled analysis of data from three randomized, placebo-controlled monotherapy trials. Clin. Ther. 2011;33(9):1150-61.
  17. Bhosale V.V., Inamdar S.C. Beneficial effects of nebivolol in comparison with atenolol on safety and tolerability in essential hypertension. J. Clin. Diagn. Res. 2014;8(6):HC01-4.
  18. Signorovitch J.E., Samuelson T.M., Ramakrishnan K., Marynchenko M., Wu E.Q., Blum S.I., Ramasamy A., Chen S. Persistence with nebivolol in the treatment of hypertension: a retrospective claims analysis. Curr. Med. Res. Opin. 2012;28(4):591-99.
  19. Chen S., Swallow E., Li N., Diener M., FarooquiS., Xie J., Wu E.Q. Real-world adherence and persistence associated with nebivolol or hydrochlorothiazide as add-on treatment for hypertension. Curr. Med. Res. Opin. 2014;30(4):637-43.
  20. Patel R.S., Sharma K.H., Kamath N.A., Patel N.H., Thakkar A.M. Cost-effectiveness analysis of nebivolol and metoprolol in essential hypertension: a pharmacoeconomic comparison of antihypertensive efficacy of beta blockers. Indian J. Pharmacol. 2014;46(5):485-89.
  21. Chen S., Tourkodimitris S., Lukic T. Economic impact of switching from metoprolol to nebivolol for hypertension treatment: a retrospective database analysis. J. Med. Econ. 2014; 17(10):685-90.
  22. Van Bortel L.M. Efficacy, tolerability and safety of nebivolol in patients with hypertension and dia betes: a post-marketing surveillance study. Eur. Rev. Med. Pharmacol. Sci. 2010;14(9):749-58.
  23. Marazzi G., Volterrani M., Caminiti G., Iaia L., Cacciotti L., Massaro R., Sposato B., Vitale C., Mercuro G., Rosano G. Effectiveness of nebivolol and hydrochlorothiazide association on blood pressure, glucose, and lipid metabolism in hypertensive patients. Adv. Ther. 2010;27(9):655-64.
  24. Schmidt A.C., Graf C., Brixius K., Scholze J. Blood pressure-lowering effect of nebivolol in hypertensive patients with type 2 diabetes mellitus: the YESTONO study. Clin. Drug. Investig. 2007;27(12):841-49.
  25. Ladage D., Reidenbach C., Rieckeheer E., Graf C., Schwinger R.H., Brixius K. Nebivolol lowers blood pressure and increases weight loss in patients with hypertension and diabetes in regard to age. J. Cardiovasc. Pharmacol. 2010;56(3):275-81.
  26. Briasoulis A., Oliva R., Kalaitzidis R., Flynn C., Lazich I., Schlaffer C., Bakris G. Effects of nebivolol on aortic compliance in patients with diabetes and maximal renin angiotensin system blockade: the EFFORT study. J. Clin. Hypertens (Greenwich). 2013;15(7):473-79.
  27. Oguz A., Uzunlulu M., Yorulmaz E., Yalcin Y., Hekim N., Fici F. Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus. Anadolu. Kardiyol. Derg. 2007;7(4):383-87.
  28. Deedwania P., Shea J, Chen W., Brener L. Effects of add-on nebivolol on blood pressure and glucose parameters in hypertensive patients with prediabetes. J. Clin. Hypertens (Greenwich). 2013;15(4):270-78.
  29. Ayers K., Byrne L.M., DeMatteo A., Brown N.J. Differential effects of nebivolol and metoprolol on insulin sensitivity and plasminogen activator inhibitor in the metabolic syndrome. Hypertension. 2012;59(4):893-98.
  30. Heitmann J., Greulich T., Reinke C., Koehler U., Vogelmeier C., Becker H.F., Schmidt A.C., Canisius S. Comparison of the effects of nebivolol and valsartan on BP reduction and sleep apnoea activity in patients with essential hypertension and OSA. Curr. Med. Res. Opin. 2010;26(8):1925-32.
  31. Caglar N., Dincer I. Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end-point (PROBE) trial. Eur. Rev. Med. Pharmacol. Sci. 2011;15(12):1359-68.
  32. Degirmenci H., Duman H., Demirelli S., Bakirci E.M., Hamur H., Inci S., Simsek Z., Askın L., Arısoy A., Lazoglu Z. Assessment of effect of irbesartan and nebivolol on the left atrium volume and deformation in the patients with mild-moderate hypertension. Eur. Rev. Med. Pharmacol. Sci. 2014; 18(6):781-89.
  33. Degirmenci H., Acikel M., Bakirci E.M., Duman H., Demirelli S., Tas H., Simsek Z., Karakelleoglu S., Aksakal E., Erol M.K. Comparison of effects of nebivolol, carvedilol and irbesartan on left ventricular hypertrophy associated with hypertension. Eur. Rev. Med. Pharmacol. Sci. 2014;18(5):630-37.
  34. Ghio S., Magrini G., Serio A., Klersy C., Fucili A., Ronaszeki A., Karpati P., Mordenti G., Capriati A., Poole-Wilson P.A., Tavazzi L.; SENIORS investigators. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy. Eur. Heart J. 2006;27(5):562-68.
  35. van Veldhuisen D.J., Cohen-Solal A., Böhm M., Anker S.D., Babalis D., Roughton M., Coats A.J., Poole-Wilson P.A., Flather M.D.; SENIORS Investigators.Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J. Am. Coll. Cardiol. 2009;53(23):2150-58.
  36. Prisada O.V., Covic A., Arghiri E., Cernomaz A., Ungureanu G. Pulse pressure, arterial compliance and Buckberg index in hypertensive patients treated with nebivolol and nitrates. Rev. Med. Chir. Soc. Med. Nat.Iasi. 2007;111(2):352-57.
  37. Davis J.T., Pasha D.N., Khandrika S., Fung M.M., Milic M., O'Connor D.T. Central hemodynamics in prehypertension: effect of the ß-adrenergic antagonist nebivolol. J. Clin. Hypertens. (Greenwich). 2013;15(1):69-74.
  38. Sendur M.A., Güven G.S., Yorgun H., Ates A.H., Canpolat U., Sunman H., Karahan S., Kaya B., Aytemir K. Effect of antihypertensive therapy on endothelial markers in newly diagnosed stage 1 hypertension: a randomized singlecentre study. Anadolu. Kardiyol. Derg. 2014; 14(4):363-69.
  39. Vitale C., Marazzi G., Iellamo F., Spoletini I., Dall'Armi V., Fini M., Volterrani M. Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: the NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study. Int. J. Cardiol. 2012;155(2):279-84.

补充文件

附件文件
动作
1. JATS XML
下载
##common.cookie##